Transplantation referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the Connect® Myeloid Disease Registry: Potential barriers to care

Benjamin Tomlinson, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio. Electronic address: Benjamin.Tomlinson@UHhospitals.org.
Marcos de Lima, Department of Hematology, Ohio State University, Columbus, Ohio.Follow
Christopher R. Cogle, University of Florida, Gainesville, Florida.Follow
Michael A. Thompson, Advocate Aurora HealthFollow
David L. Grinblatt, NorthShore University Health System, Evanston, Illinois.
Daniel A. Pollyea, University of Colorado Cancer Center, Aurora, Colorado.
Rami S. Komrokji, Moffitt Cancer Center, Tampa, Florida.
Gail J. Roboz, Weill Cornell College of Medicine, New York, New York.
Michael R. Savona, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Mikkael A. Sekeres, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Mehrdad Abedi, University of California Davis, Sacramento, California.Follow
Guillermo Garcia-Manero, University of Texas MD Anderson Cancer Center, Houston, Texas.
Sandra E. Kurtin, University of Arizona Cancer Center, Tucson, Arizona.
Jaroslaw P. Maciejewski, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Jay L. Patel, University of Utah and ARUP Laboratories, Salt Lake City, Utah.
Dennis A. Revicki, Outcomes Research Consulting, Sarasota, Florida.
Tracy I. George, University of Utah and ARUP Laboratories, Salt Lake City, Utah.
E Dawn Flick, Bristol Myers Squibb, Princeton, New Jersey.
Pavel Kiselev, Bristol Myers Squibb, Princeton, New Jersey.
Chrystal U. Louis, Formerly Bristol Myers Squibb, Princeton, New Jersey.
Irene S. DeGutis, Bristol Myers Squibb, Princeton, New Jersey.
Melissa Nifenecker, Bristol Myers Squibb, Princeton, New Jersey.
Harry P. Erba, Duke University, Durham, North Carolina.
David P. Steensma, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bart L. Scott, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Abstract

Background: Hematopoietic stem cell transplantation (HCT) is indicated for patients with higher-risk (HR) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Age, performance status, patient frailty, comorbidities, and non-clinical factors (eg, cost, distance to site) are all recognized as important clinical factors that can influence HCT referral patterns and patient outcomes. However, the proportion of eligible patients referred for HCT in routine clinical practice is largely unknown.

Objective: This study aimed to assess patterns of consideration for HCT among patients with HR-MDS and AML enrolled in the Connect® Myeloid Disease Registry, at community/government (CO/GOV)- or academic (AC)-based sites, as well as to identify factors associated with transplant referral rates.

Study design: We assessed patterns of consideration for, and completion of, HCT among patients with HR-MDS and AML enrolled between December 12, 2013 and March 6, 2020 in the Connect® Myeloid Disease Registry at 164 CO/GOV and AC sites. Registry sites recorded whether patients were considered for transplant at baseline and at each follow-up visit. The following answers were possible: "considered potentially eligible", "not considered potentially eligible", or "not assessed". Sites also recorded whether patients subsequently underwent HCT at each follow-up visit. Comparison of transplant consideration rates between CO/GOV and AC sites was performed using multivariable logistic regression analysis with covariates for age and comorbidity.

Results: Among the 778 patients with HR-MDS or AML enrolled in the Registry, patients at CO/GOV sites (27.9%) were less likely to be considered potentially eligible for HCT than patients at AC sites (43.9%; (P < .0001). Multivariable logistic regression analysis with factors for age (

Conclusions: These findings suggest many patients with HR-MDS and AML who may be candidates for HCT are not receiving assessment or consideration for transplant in clinical practice. In addition, treatment at CO/GOV sites and age are still significant barriers to ensuring all potentially eligible patients are assessed for HCT.

Document Type

Article

PubMed ID

37086851

Teammate Access


 

Share

COinS